Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy

Novara Atherosclerosis Study Group (NAS)

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Background: Increased comorbidities and a perceived high-bleeding risk often prevent the use of dual antiplatelet therapy (DAPT) in female patients. However, more aggressive antiplatelet treatment would certainly offer additional outcome benefits in coronary artery disease, especially among diabetic patients. The aim of the present study was to evaluate the gender differences in high-residual on treatment platelet reactivity (HRPR) among diabetic patients treated with DAPT. Methods: Our population is represented by a consecutive cohort of diabetic patients treated with DAPT (ASA + clopidogrel, ticagrelor or dose-adjusted prasugrel) for an acute coronary syndrome or elective PCI, undergoing platelet reactivity assessment at 30–90 days post-discharge. Aggregation was assessed by multiple-electrode aggregometry and in diabetic patients naïve to antiplatelet therapy, by light transmission aggregometry, surface expression of P-selectin and plasma concentration of Thromboxane B2. Results: We included 472 patients, 113 (23.9%) women. Female gender was associated with more advanced age, and increased comorbidities. Mean platelet reactivity did not differ according to gender. The rate of HRPR was similar in women as compared to men (for ASA: adjusted OR[95%CI] = 0.59[0.27–1.33], p = 0.21, for ADP-antagonists: adjusted OR[95%CI] = 1.24[0.25–1.80], p = 0.27), however, the benefits of the new ADP-antagonists on platelet reactivity were lower in women than in men (p interaction = 0.01). No impact of gender on platelet reactivity was confirmed among 50 diabetic patients naïve to antiplatelet therapy. Conclusions: Among diabetic patients receiving dual antiplatelet therapy gender does not affect platelet reactivity or high-on treatment platelet reactivity. However, the enhanced platelet inhibition provided by the new-ADP antagonists of new-ADP antagonists could be mitigated in women.

Lingua originaleInglese
pagine (da-a)1144-1149
Numero di pagine6
RivistaCardiovascular Revascularization Medicine
Volume21
Numero di pubblicazione9
DOI
Stato di pubblicazionePubblicato - set 2020

Fingerprint

Entra nei temi di ricerca di 'Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy'. Insieme formano una fingerprint unica.

Cita questo